The Economic Burden of Pediatric Postconcussive Syndrome

Clin J Sport Med. 2020 Sep;30(5):e154-e155. doi: 10.1097/JSM.0000000000000732.

Abstract

Objective: To estimate the direct costs of pediatric postconcussive syndrome (PCS).

Design: Retrospective cohort study.

Setting: Subspecialty sports medicine clinics of a large pediatric tertiary care network in the United States.

Patients: One hundred fifty-four patients aged 5 to 18 years with PCS, evaluated between 2010 and 2011.

Assessment of independent variables: Direct costs included visits to sports medicine clinic, visio-vestibular therapy, homebound education, subspecialist referral, and prescription-only medications (amantadine and amitriptyline), all measured beginning at 28 days after injury.

Main outcome measures: Postconcussive syndrome was defined as persistence beyond 28 days from injury.

Results: The cost incurred by each PCS patient for sports medicine visits was $1575, for visio-vestibular therapy was $985, for homebound tutoring was $55, for prescription medications was $22, and for subspecialist referral was $120, totaling $3557 per patient, with a 95% confidence interval range of $2886 to $4257.

Conclusions: Given the high economic costs of PCS determined in this study, therapies that mitigate this syndrome may have the potential to be cost-effective and even cost saving.

MeSH terms

  • Adolescent
  • Amantadine / economics
  • Amitriptyline / economics
  • Child
  • Child, Preschool
  • Confidence Intervals
  • Direct Service Costs*
  • Education / economics
  • Humans
  • Outcome Assessment, Health Care
  • Post-Concussion Syndrome / economics*
  • Post-Concussion Syndrome / therapy
  • Referral and Consultation / economics
  • Retrospective Studies
  • Sports Medicine / economics
  • Time Factors
  • United States

Substances

  • Amitriptyline
  • Amantadine